{"id":357686731,"generated_unique_award_id":"ASST_NON_R21CA309305_075","fain":"R21CA309305","uri":"R21CA309305-2122398921","category":"grant","type":"F001","type_description":"GRANT","description":"A PILOT ADAPTIVE TRIAL OF FITTRACK CHATBOT, NURSE NAVIGATOR, AND PEER NAVIGATOR TO PROMOTE FIT SCREENING AMONG RURAL RESIDENTS. - PROJECT SUMMARY & ABSTRACT BACKGROUND: RURAL RESIDENTS EXPERIENCE HIGHER COLORECTAL CANCER (CRC) INCIDENCE AND MORTALITY RATES THAN THEIR URBAN COUNTERPARTS. ADHERENCE TO CRC SCREENING IS ESSENTIAL FOR EARLY DETECTION, TIMELY TREATMENT, AND REDUCED MORTALITY. THE FECAL IMMUNOCHEMICAL TEST (FIT) IS A PREFERRED SCREENING METHOD AMONG RURAL POPULATIONS DUE TO ITS NON-INVASIVE NATURE, AFFORDABILITY, AND AT-HOME CONVENIENCE. PATIENT NAVIGATION PLAYS A CRUCIAL ROLE IN INCREASING FIT COMPLETION RATES BUT FACES STRUCTURAL AND LOGISTICAL CHALLENGES. WHILE ADAPTIVE, STEPPED-CARE PATIENT NAVIGATION INTERVENTIONS HAVE BEEN DEVELOPED TO IMPROVE SCALABILITY AND COST-EFFECTIVENESS, THEY HAVE NOT BEEN FAILED TO ACCOUNT FOR INDIVIDUAL SOCIODEMOGRAPHIC FACTORS AND EVOLVING PATIENT NEEDS IN REAL TIME, AND HAVE NOT DETERMINED THE OPTIMAL TIMING OR TYPE OF PERSON-LED NAVIGATION. THE PRIMARY GOAL OF THIS STUDY IS TO OPTIMIZE A NOVEL ADAPTIVE PATIENT NAVIGATION MODEL USING A TWO-STAGE SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMIZED TRIAL (SMART) TO PROMOTE FIT SCREENING AMONG RURAL RESIDENTS. IN STAGE 1, THIS STUDY WILL EVALUATE CHATBOT-BASED NAVIGATION (FITTRACK) VERSUS STANDARD SMS REMINDERS AS AN INITIAL ASSISTIVE TOOL AND DETERMINE THE OPTIMAL TIMING FOR INTRODUCING ADDITIONAL PERSON-LED SUPPORT. IN STAGE 2, THIS STUDY WILL ASSESS THE OPTIMAL TYPE OF PERSON-LED SUPPORT, COMPARING NURSE NAVIGATORS AND PEER NAVIGATORS. SPECIFIC AIMS: 1) EVALUATE THE FEASIBILITY AND ACCEPTABILITY OF THE DIGITAL INTERVENTION (4-WEEK SMS REMINDERS, 4-WEEK FITTRACK CHATBOT, AND 12- WEEK FIT TRACK CHATBOT), SUPPLEMENTAL PERSON-LED NAVIGATION (NURSE VS. PEER), AND ADAPTIVE INTERVENTIONS (DIGITAL INTERVENTION PLUS PERSON-LED NAVIGATION); 2) EVALUATE THE PRELIMINARY EFFECTIVENESS OF THESE INTERVENTIONS; 3) UNDERSTAND STEP-SPECIFIC CHALLENGES AND SUPPORTS NEEDED IN COMPLETING FIT. INNOVATION: THIS STUDY IS HIGHLY INNOVATIVE AS IT TAILORS TO INDIVIDUAL SOCIODEMOGRAPHIC FACTORS AND REAL-TIME NEEDS THROUGH THE INTEGRATION OF AI- BASED CHATBOT TECHNOLOGY, UTILIZES A NOVEL TRIAL DESIGN (I.E., SMART) TO INFORM THE DEVELOPMENT OF AN ADAPTIVE MODEL, AND DIRECTLY ADDRESSES THE UNIQUE CHALLENGES FACED BY RURAL RESIDENTS. SIGNIFICANCE: ALIGNED WITH PA- 25-295, THIS STUDY ACCELERATES PRIORITY INITIATIVES BY IDENTIFYING OPTIMAL TYPE AND TIMING OF DIGITAL AND PERSON- ASSISTED NAVIGATION APPROACHES TO IMPROVE CRC SCREENING ADHERENCE AMONG RURAL POPULATIONS. ULTIMATELY, THESE FINDINGS WILL SUPPORT THE DEVELOPMENT OF A SCALABLE, ADAPTIVE, AND COST-EFFECTIVE PATIENT NAVIGATION INTERVENTION, ADVANCING CANCER PREVENTION AND EARLY DETECTION EFFORTS IN POPULATIONS WITH HIGH CANCER BURDEN.","subaward_count":0,"total_subaward_amount":null,"total_subsidy_cost":0.0,"total_loan_value":0.0,"total_obligation":380554.0,"date_signed":"2026-04-27","base_and_all_options":null,"base_exercised_options":null,"non_federal_funding":0.0,"total_funding":380554.0,"total_account_outlay":21434.84,"total_account_obligation":380554.0,"account_outlays_by_defc":[{"code":"Q","amount":21434.84}],"account_obligations_by_defc":[{"code":"Q","amount":380554.0}],"record_type":2,"cfda_info":[{"applicant_eligibility":"The awardee will be a university, college, hospital, public agency, nonprofit research institution or for-profit organization that submits an application and receives a grant or cooperative agreement for support of research by a named principal investigator. SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed, and have no more than 500 employees). Primary employment (more than one- half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concern (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which \"partner\" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.","beneficiary_eligibility":"Beneficiary eligibility is the same as applicant eligibility.\nAny nonprofit or for-profit organization, company, or institution engaged in biomedical research on cancer.","cfda_federal_agency":"NATIONAL INSTITUTES OF HEALTH, HEALTH AND HUMAN SERVICES, DEPARTMENT OF","cfda_number":"93.393","cfda_objectives":"To identify cancer risks and risk reduction strategies, to identify factors that cause cancer in humans, and to discover and develop mechanisms for cancer prevention and preventive interventions in humans. Research programs include: (1) chemical, physical and molecular carcinogenesis; (2) screening, early detection and risk assessment, including biomarker discovery, development and validation; (3) epidemiology; (4) nutrition and bioactive food components; (5) immunology and vaccines; (6) field studies and statistics; (7) cancer chemoprevention and interception; (8) pre-clinical and clinical agent development; (9) organ site studies and clinical trials; (10) health-related quality of life and patient-centered outcomes; and (11) supportive care and management of symptoms and toxicities. Small Business Innovation Research (SBIR) program: To expand and improve the SBIR program; to stimulate technical innovation; to increase private sector commercialization of innovations derived from Federal research and development funding; to increase small business participation in Federal research and development; and to foster and encourage participation in innovation and entrepreneurship by women and socially/economically disadvantaged persons. \n Small Business Technology Transfer (STTR) program: To stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer through cooperative research and development between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development funding, and foster participation in innovation and entrepreneurship by women and socially/economically disadvantaged persons.","cfda_obligations":"(Cooperative Agreement) FY 24$135,517,100.00; FY 25$143,608,401.00; FY 26 est $93,360,343.00; - (Grant) FY 24$619,428,059.00; FY 25$690,906,111.00; FY 26 est $426,735,933.00; - ","cfda_popular_name":"Cancer Cause and Prevention Research","cfda_title":"Cancer Cause and Prevention Research","cfda_website":"http://www.cancer.gov","federal_action_obligation_amount":380554.0,"non_federal_funding_amount":0.0,"sam_website":"https://sam.gov/fal/23b5600e32f94cb2bf12693c1ace2a59/view","total_funding_amount":380554.0}],"transaction_obligated_amount":380554.0,"funding_agency":{"id":830,"has_agency_page":true,"toptier_agency":{"name":"Department of Health and Human Services","code":"075","abbreviation":"HHS","slug":"department-of-health-and-human-services"},"subtier_agency":{"name":"National Institutes of Health","code":"7529","abbreviation":"NIH"},"office_agency_name":"NIH National Cancer Institute"},"awarding_agency":{"id":830,"has_agency_page":true,"toptier_agency":{"name":"Department of Health and Human Services","code":"075","abbreviation":"HHS","slug":"department-of-health-and-human-services"},"subtier_agency":{"name":"National Institutes of Health","code":"7529","abbreviation":"NIH"},"office_agency_name":"NIH National Cancer Institute"},"period_of_performance":{"start_date":"2026-05-01","end_date":"2028-04-30","last_modified_date":"2026-10-30"},"recipient":{"recipient_hash":"6a863c9b-365c-816d-1f3a-a0096107ff16-C","recipient_name":"LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER NEW ORLEANS","recipient_uei":"M7KCJ79FAVH5","recipient_unique_id":null,"parent_recipient_hash":"b38d868b-ee6b-6fb1-d7b8-e887be5fd132-P","parent_recipient_name":"LOUISIANA STATE UNIVERSITY SYSTEM","parent_recipient_uei":"D6W1MELL67T9","parent_recipient_unique_id":null,"business_categories":["Higher Education","Higher Education (Public)"],"location":{"location_country_code":"USA","country_name":"UNITED STATES","state_code":"LA","state_name":"LOUISIANA","city_name":"NEW ORLEANS","county_code":"071","county_name":"ORLEANS","address_line1":"433 BOLIVAR ST RM 619","address_line2":null,"address_line3":null,"congressional_code":"02","zip4":"7021","zip5":"70112","foreign_postal_code":null,"foreign_province":null}},"executive_details":{"officers":[{"name":null,"amount":null},{"name":null,"amount":null},{"name":null,"amount":null},{"name":null,"amount":null},{"name":null,"amount":null}]},"place_of_performance":{"location_country_code":"USA","country_name":"UNITED STATES","county_code":"071","county_name":"ORLEANS","city_name":"NEW ORLEANS","state_code":"LA","state_name":"LOUISIANA","congressional_code":"02","zip4":"7021","zip5":"70112","address_line1":null,"address_line2":null,"address_line3":null,"foreign_province":null,"foreign_postal_code":null},"total_outlay":21434.84,"funding_opportunity":{"number":"PA-25-295","goals":"<P>THE OVERALL GOALS OF THIS NOFO IS TO REDUCE CANCER RISK, INCIDENCE, MORBIDITY, AND MORTALITY AND ENHANCE QUALITY OF LIFE IN CANCER SURVIVORS THROUGH AN ORDERLY SEQUENCE FROM RESEARCH ON INTERVENTIONS AND THEIR IMPACT IN DEFINED POPULATIONS TO THE BROAD, SYSTEMATIC APPLICATION OF THE RESEARCH RESULTS THROUGH DISSEMINATION AND DIFFUSION STRATEGIES.</P>"}}